Our Vision In Action
Our platform enables discovery of high-quality, novel molecules more rapidly, at lower cost
Our world-class drug discovery team is leveraging our computational platform and massive computing power to advance our preclinical pipeline and a portfolio of programs in collaboration with leading biotech and pharmaceutical companies.
|
SGR-1505 (MALT1)Relapsed /
Resistant Non-Hodgkin's Lymphoma |
|
Schrödinger |
|---|---|---|
|
SGR-2921 (CDC7)Hematological Cancers and Solid Tumors |
|
Schrödinger |
|
Wee1Gynecological Cancers and other Solid Tumors |
|
Schrödinger |
|
4 UndisclosedOncology |
|
Schrödinger |
| 2 UndisclosedImmunology |
|
Schrödinger |
|
SOS1 / KRASKRAS-Driven Cancers |
|
Schrodinger and Bristol Myers Squibb |
| 2 UndisclosedOncology |
|
Schrodinger and Bristol Myers Squibb |
| UndisclosedImmunology |
|
Schrodinger and Bristol Myers Squibb |
| UndisclosedNeurology |
|
Schrodinger and Bristol Myers Squibb |
| Protein DegradersOncology,
Immunology and Neurology |
|
Schrodinger and Bristol Myers Squibb |
| UndisclosedOncology |
|
Schrodinger and Takeda |
| DNA Damage ResponseOncology |
|
Schrodinger and ZAI Lab |
|
TIBSOVO*
|
|
|---|---|
|
IDHIFA*
|
|
|
Oncology
|
|
|
Oncology
|
|
|
Antifungal
|
|
|
Oncology
|
|
|
Inflammatory Bowel Diseases
|
|
|
Fibrosis
|
|
|
GI Indications
|
|
|
Solid Tumors
|
|
|
Undisclosed
|
|
|
Metabolic Diseases**
|
|
|
Autoimmune and Inflammatory Diseases
|
|
|
Immuno-oncology
|
|
|
Autoimmune Disease and Cancer
|
|
|
Immuno-oncology
|
|
|
Undisclosed Targets
|
|
|
Undisclosed
|
|
|
Sleep Disorders
|
|
|
Autoimmune Disease
|
|
|
Oncology
|
|
|
Pulmonary Arterial Hypertension
|
|
|
Type 2 Diabetes / Obesity
|
|
|
Idiopathic Pulmonary Fibrosis
|
|
|
Oncology
|
|
* Acquired by Servier
** Acquired by Gilead